What Happened to Opioid Epidemic?

The Opioid Epidemic, a multifaceted public health crisis, has gripped the United States for decades, evolving through several distinct waves. Initially fueled by the over-prescription of opioid painkillers in the late 1990s, it transitioned to a surge in heroin use around 2010, and then to the dominance of synthetic opioids, particularly fentanyl, starting around 2013. By 2023, synthetic opioids accounted for approximately 70% of all overdose fatalities, reaching a peak of nearly 110,000 annual drug overdose deaths.

Recent data, however, indicates a significant shift. Provisional CDC data shows a historic decline in overdose deaths, with a 24.4% drop between 2023 and 2024, and further decreases into 2025 and early 2026. The estimated number of drug overdose deaths in the U.S. for the 12 months ending February 2026 was 68,641, a 12.1% decline from 2025. This downturn is largely attributed to a decrease in fentanyl-related deaths, both alone and in combination with stimulants. Experts suggest this decline may be due to a combination of expanded naloxone access, increased public awareness, intensified prevention efforts, and potential shifts in the illicit drug supply, possibly including a supply shock of precursor chemicals from China.

Despite these encouraging trends, the crisis is far from over. Fentanyl remains the leading cause of accidental drug overdose deaths, and the drug supply is increasingly toxic and unpredictable, with nearly 60% of opioid-related deaths involving more than one dangerous substance. Concerns are rising about increasing overdose deaths involving stimulants without fentanyl, as well as the growing presence of xylazine, a veterinary sedative, in the illicit drug supply. The demographic profile of those affected is also shifting, with the crisis increasingly impacting older adults and persistent racial disparities.

In response to the crisis, significant legal and financial developments have occurred. Purdue Pharma, a key player in the initial opioid crisis, officially dissolved on May 1, 2026, as its bankruptcy concluded. Its assets were transferred to Knoa Pharma LLC, a new public benefit corporation dedicated to public health, and the Sackler family is permanently barred from selling opioids in the U.S. Billions of dollars from national opioid settlements with major distributors (McKesson, Cardinal Health, AmerisourceBergen), manufacturers (Johnson & Johnson), and pharmacy chains (CVS, Walgreens, Walmart, Teva, Allergan) are being distributed to states, counties, and Tribal Nations over many years to fund abatement programs. As of July 10, 2026, approximately $57.7 billion has been allocated nationwide. However, the effective use of these funds is a focus, with a 2026 National Roadmap providing guidance on spending priorities, including harm reduction, treatment, and recovery services.

Federal policy in 2025 and 2026 has introduced new complexities. The Trump administration has implemented or proposed significant cuts and disruptions to federal opioid response programs, including withholding fentanyl response grants and recommending elimination of naloxone distribution programs. The administration's 'Great American Recovery Initiative' in January 2026, while adding some medications for opioid use disorder (MOUD) as eligible for federal funding, also emphasized a move away from certain harm reduction strategies, signaling greater political interference in public health approaches. This federal policy volatility creates ongoing risk for the treatment and prevention infrastructure that relies on both settlement funds and federal support.